ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia

Background and objectives: DNA hypermethylation has been linked to poor treatment outcome in childhood acute lymphoblastic leukemia (ALL). Genes differentially methylated in the chemoresponsive pre-B-ALL compared to chemoresistant pre-B-ALL cases provide potential prognostic markers. Methods: DNA me...

Full description

Bibliographic Details
Main Authors: Abdullah, Maha, Choo, Chee Wei, Alias, Hamidah, Abdul Rahman, Eni Juraidah, Mohd Ibrahim, Hishahshah, Jamal, Rahman, Hussin, Noor Hamidah
Format: Article
Language:English
Published: Maney Publishing 2017
Online Access:http://psasir.upm.edu.my/id/eprint/60765/
http://psasir.upm.edu.my/id/eprint/60765/1/ADAMTSL5%20and%20CDH11%20putative%20epigenetic%20markers%20for%20therapeutic%20resistance%20in%20acute%20lymphoblastic%20leukemia.pdf
_version_ 1848854269255483392
author Abdullah, Maha
Choo, Chee Wei
Alias, Hamidah
Abdul Rahman, Eni Juraidah
Mohd Ibrahim, Hishahshah
Jamal, Rahman
Hussin, Noor Hamidah
author_facet Abdullah, Maha
Choo, Chee Wei
Alias, Hamidah
Abdul Rahman, Eni Juraidah
Mohd Ibrahim, Hishahshah
Jamal, Rahman
Hussin, Noor Hamidah
author_sort Abdullah, Maha
building UPM Institutional Repository
collection Online Access
description Background and objectives: DNA hypermethylation has been linked to poor treatment outcome in childhood acute lymphoblastic leukemia (ALL). Genes differentially methylated in the chemoresponsive pre-B-ALL compared to chemoresistant pre-B-ALL cases provide potential prognostic markers. Methods: DNA methylation profiles of five B-ALL childhood patients who achieved morphological complete remission (chemoresponsive) and five B-ALL patients who did not (chemoresistant) after induction treatments as well as four normal controls were compared on 27 000 CpG sites microarray chips. Subsequently, methylation-specific polymerase chain reaction (MSP) on selected hypermethylated genes was conducted on an additional 37 chemoresponsive and 9 chemoresistant B-ALL samples and 2 normal controls. Results: Both methods were found to be highly correlated. Unsupervised principal component analysis showed that the chemotherapy-responsive and -resistant B-ALL patients could be segregated from one another. Selection of segregated genes at high stringency identified two potential genes (CDH11 and ADAMTSL5). MSP analysis on the larger cohort of samples (42 chemoresponsive, 14 chemoresistant B-ALL samples and 6 normal controls) revealed significantly higher rates of hypermethylation in chemoresistant samples for ADAMTSL5 (93 vs. 38%; p = 0.0001) and CDH11 (79% vs. 40%, p < 0.01). All control cases remained unmethylated. Conclusion: Chemoresistant B-ALL patients are associated with increased methylation in ADAMTSL5 and CDH11. These findings need to be validated in a larger group of patients, and the functional biological and prognostic significance of differential methylation needs to be studied further.
first_indexed 2025-11-15T11:07:11Z
format Article
id upm-60765
institution Universiti Putra Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T11:07:11Z
publishDate 2017
publisher Maney Publishing
recordtype eprints
repository_type Digital Repository
spelling upm-607652019-03-28T02:40:55Z http://psasir.upm.edu.my/id/eprint/60765/ ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia Abdullah, Maha Choo, Chee Wei Alias, Hamidah Abdul Rahman, Eni Juraidah Mohd Ibrahim, Hishahshah Jamal, Rahman Hussin, Noor Hamidah Background and objectives: DNA hypermethylation has been linked to poor treatment outcome in childhood acute lymphoblastic leukemia (ALL). Genes differentially methylated in the chemoresponsive pre-B-ALL compared to chemoresistant pre-B-ALL cases provide potential prognostic markers. Methods: DNA methylation profiles of five B-ALL childhood patients who achieved morphological complete remission (chemoresponsive) and five B-ALL patients who did not (chemoresistant) after induction treatments as well as four normal controls were compared on 27 000 CpG sites microarray chips. Subsequently, methylation-specific polymerase chain reaction (MSP) on selected hypermethylated genes was conducted on an additional 37 chemoresponsive and 9 chemoresistant B-ALL samples and 2 normal controls. Results: Both methods were found to be highly correlated. Unsupervised principal component analysis showed that the chemotherapy-responsive and -resistant B-ALL patients could be segregated from one another. Selection of segregated genes at high stringency identified two potential genes (CDH11 and ADAMTSL5). MSP analysis on the larger cohort of samples (42 chemoresponsive, 14 chemoresistant B-ALL samples and 6 normal controls) revealed significantly higher rates of hypermethylation in chemoresistant samples for ADAMTSL5 (93 vs. 38%; p = 0.0001) and CDH11 (79% vs. 40%, p < 0.01). All control cases remained unmethylated. Conclusion: Chemoresistant B-ALL patients are associated with increased methylation in ADAMTSL5 and CDH11. These findings need to be validated in a larger group of patients, and the functional biological and prognostic significance of differential methylation needs to be studied further. Maney Publishing 2017 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/60765/1/ADAMTSL5%20and%20CDH11%20putative%20epigenetic%20markers%20for%20therapeutic%20resistance%20in%20acute%20lymphoblastic%20leukemia.pdf Abdullah, Maha and Choo, Chee Wei and Alias, Hamidah and Abdul Rahman, Eni Juraidah and Mohd Ibrahim, Hishahshah and Jamal, Rahman and Hussin, Noor Hamidah (2017) ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia. Hematology, 22 (7). 386 - 391. ISSN 1024-5332, ESSN: 1607-8454 https://www.tandfonline.com/doi/full/10.1080/10245332.2017.1299417 10.1080/10245332.2017.1299417
spellingShingle Abdullah, Maha
Choo, Chee Wei
Alias, Hamidah
Abdul Rahman, Eni Juraidah
Mohd Ibrahim, Hishahshah
Jamal, Rahman
Hussin, Noor Hamidah
ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia
title ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia
title_full ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia
title_fullStr ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia
title_full_unstemmed ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia
title_short ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia
title_sort adamtsl5 and cdh11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia
url http://psasir.upm.edu.my/id/eprint/60765/
http://psasir.upm.edu.my/id/eprint/60765/
http://psasir.upm.edu.my/id/eprint/60765/
http://psasir.upm.edu.my/id/eprint/60765/1/ADAMTSL5%20and%20CDH11%20putative%20epigenetic%20markers%20for%20therapeutic%20resistance%20in%20acute%20lymphoblastic%20leukemia.pdf